Anti-Human ANXA1 (Clone CPTC-ANXA1-4) – Purified No Carrier Protein

ANXA1 synthetic peptide AAYLQETGKPLDETLK

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

SAIC-13B-19 H3/L3 activity is directed against human ANXA1 peptide sequence AAYLQETGKPLDETLK.

CPTC-ANXA1-4

ANXA1 is a calcium-dependent phospholipid binding protein involved in cell signal transduction, cell proliferation, angiogenesis, apoptosis, differentiation, and both pro- and anti- inflammatory responses¹. The nature of the inflammatory response depends on the ligand as well as ANXA1’s participation in the secretion and function of glucocorticoids. ANXA1 localizes to the cytoplasm, nucleus, cell membrane or may be secreted depending on its cellular activity. In normal metabolism, ANXA1 promotes cardiac neovascularization and repair and is involved in angiogenesis during placental development. ANXA1 also participates in cell chemotaxis via the chemokine response and is thought to play a role in the infiltration of tumor immune cells. Dysregulation of ANXA1 in the tumor microenvironment can promote or inhibit proliferation, metastasis, angiogenesis, and immune escape, depending on cell type and dysregulation. Upregulation or downregulation of ANXA1 can both occur, with tumor specific consequences.

SAIC-13B-19 H3/L3 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from human ANXA1, AAYLQETGKPLDETLK². SAIC-13B-19 H3/L3 also binds ANXA1 by indirect ELISA³. SAIC-13B-19 H3/L3 does not detect ANXA1 by immunohistochemistry, immunofluorescence, or Western blotting.

Annexin A1 (ANXA1) is abundantly expressed in the cytosols of resting neutrophils, monocytes, and macrophages as well as in peripheral blood T cells. Upon cell activation, ANXA1 preferentially localizes to the cytosolic face of the plasma membrane or may be secreted. ANXA1 is present in extracellular blood vesicles in response to wounding or inflammation.

Ca2+, S100A11

1 Li L, Wang B, Zhao S, et al. Int Immunopharmacol. 131:111854. 2024.
2 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
3 https://antibodies.cancer.gov/detail/CPTC-ANXA1-4#CPTC-ANXA1-4